R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Jan

Today In Oncology

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care

AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis

Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction

AI May Boost Efficacy of Cancer Care but Physicians Remain Critical to Decision Making

Novel AI Platform May Help Identify Patients Likely to Benefit Most From Clinical Trials